Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML. In addition to suppressing leukemogenic transcriptional programs and promoting leukemic differentiation, menin inhibition has been shown to modulate epigenetic states linked to antigen presentation and immune recognition. These properties provide a strong biological rationale for evaluating revumenib as maintenance therapy following alloHCT, with the goal of suppressing residual leukemic clones while preserving or enhancing GVL activity during immune reconstitution.
Aged ≥18 years at the time of signing informed consent
Able to provide written informed consent personally or via a legally authorized representative in accordance with applicable regulatory and institutional requirements
Willing and able to comply with all study procedures and available for the duration of the study
Planned allo-HCT using bone marrow or peripheral blood stem cell graft source.
≥5% bone marrow blasts
Circulating blasts within 14 days before conditioning
CNS or other extramedullary disease
Other active malignancy that, in the investigator's judgment, could interfere with safety or efficacy assessment
Center for International Blood and Marrow Transplant Research
Lead sponsor
National Marrow Donor Program
Collaborator
Dana-Farber Cancer Institute
Collaborator